Results 51 to 60 of about 50,964 (281)

Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators

Asian Journal of Andrology, 2023
Prostate cancer is one of the most common diseases in men worldwide. Surgery, radiation therapy, and hormonal therapy are effective treatments for early-stage prostate cancer. However, the development of castration-resistant prostate cancer has increased
Sayuri Takahashi, Ichiro Takada
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. [PDF]

PLoS ONE, 2012
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may ...
Reema A Ishteiwy, Toby M Ward, Derek M Dykxhoorn, Kerry L Burnstein   +3 more
doaj   +1 more source

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang, Dongxu Zhang, Dongyuan Liu, Da Lin, Hao Wang   +4 more
wiley   +1 more source

A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? [PDF]

, 2021
Context: The role of immune checkpoint inhibition (ICI) in the treatment of prostate cancer (PC) still remains elusive. It has been proposed that combination of ICI with other molecules increases the efficacy of immunotherapy in PC.
Necchi, A, Valerio, M., van den Bergh, RCN, Marra, G., Mathieu, R, Kretschmer, A, Tsaur, I, Kretschmer, A., Gandaglia, G, Heidegger, I, Tilki, D., Ceci, F, Ceci, F., Kasivisvanathan, V., Surcel, C., Kasivisvanathan, V, Tsaur, I., Surcel, C, Mathieu, R., Necchi, A., Tilki, D, EAU-YAU Prostate Cancer Working Party, Pircher, A, Pircher, A., Heidegger, I., Gandaglia, G., Marra, G, Valerio, M, Thibault, C, Thibault, C.   +29 more
core   +1 more source

Aggressive Variants of Castration-Resistant Prostate Cancer [PDF]

Clinical Cancer Research, 2014
Abstract A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly ...
Himisha, Beltran, Scott, Tomlins, Ana, Aparicio, Vivek, Arora, David, Rickman, Gustavo, Ayala, Jiaoti, Huang, Lawrence, True, Martin E, Gleave, Howard, Soule, Christopher, Logothetis, Mark A, Rubin   +11 more
openaire   +2 more sources

A Fully Human Engineered Bone Niche With Endogenous Osteoclastogenesis Reveals Osteoclast‐Dependent Osteomimicry in Prostate Cancer Cells

Advanced Healthcare Materials, EarlyView.
A human 3D bone niche integrating osteoblasts and osteoclasts enables co‐culture with prostate cancer cell lines and patient‐derived organoids. The engineered niche (i) models aspects of reciprocal phenotypic regulation between osteoblasts and cancer cells, (ii) captures osteoclast‐enhanced osteomimicry in tumor cells, and (iii) establishes a ...
Andrea Mazzoleni, Robin Dolgos, Thomas Menter, Boris Dasen, Arnaud Scherberich, Clémentine Le Magnen, Manuele G. Muraro, Ivan Martin   +7 more
wiley   +1 more source

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

, 2016
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide.
Blagg, J, Welti, J, Sharp, A, de Bono, JS   +3 more
core   +1 more source

HER3 Is an Actionable Target in Advanced Prostate Cancer.

, 2021
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically.
Bertan, C, Crespo, M, Guo, C, D'Ambrosio, M, Sharp, A, Rekowski, J, Swain, A, Carreira, S, Paschalis, A, Troiani, M, Ning, J, Gurel, B, de Bono, J, Sumanasuriya, S, PCF/SU2C International Prostate Cancer Dream Team,, Gil, V, Christova, R, Califano, A, Seed, G, Brina, D, Workman, P, Vasciaveo, A, Pereira, R, Dolling, D, Yuan, W, Flohr, P, Sheehan, B, Fowler, G, Rescigno, P, Neeb, A, Ferreira, A, Riisnaes, R, Alajati, A, Alimonti, A, Miranda, S, Buroni, L, Tunariu, N, Lambros, M, Aversa, C, Figueiredo, I, Shen, MM, Bianchini, D, Welti, J, Clarke, M, Boysen, G   +44 more
core   +1 more source

Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer

Pharmaceutics, 2021
There have been several studies that have linked elevated scavenger receptor class b type 1 (SR-B1) expression and activity to the development and progression of castration-resistant prostate cancer (CRPC).
Mitali Pandey, Grace Cuddihy, Jacob A. Gordon, Michael E. Cox, Kishor M. Wasan   +4 more
doaj   +1 more source